VPC
TSHA icon

Vestal Point Capital’s Taysha Gene Therapies TSHA Stock Holding History

Vestal Point Capital’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$132M Buy
19,415,000
+1,415,000
+8% +$8.37M 3.09% 8
2026
Q1 		$80.5M Buy
18,000,000
+4,250,000
+31% +$19.8M 2.25% 13
2025
Q4 		$75.6M Buy
13,750,000
+8,250,000
+150% +$40.1M 2.57% 11
2025
Q3 		$18M Buy
5,500,000
+2,500,000
+83% +$7.08M 0.81% 44
2025
Q2 		$6.93M Buy
+3,000,000
New +$6.52M 0.36% 49

Other funds holding TSHA

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Vestal Point Capital's TSHA Position: Q2 2026 in Review

Vestal Point Capital increased its Taysha Gene Therapies (TSHA) stake by 7.9% in Q2 2026, buying an estimated $8.37M and bringing the position to 19,415,000 shares worth $132M. The position accounts for 3.09% of the portfolio, ranked #8.

Vestal Point Capital first reported a position in TSHA in Q2 2025 and has held it in 5 quarters since. 208 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

  • Vestal Point Capital held 19,415,000 shares of Taysha Gene Therapies worth $132M as of Q2 2026.
  • Vestal Point Capital bought 1,415,000 Taysha Gene Therapies shares in Q2 2026, an estimated $8.37M.
  • Taysha Gene Therapies made up 3.09% of Vestal Point Capital's portfolio in Q2 2026, its #8 holding.
  • Vestal Point Capital first reported a position in Taysha Gene Therapies in Q2 2025 and has held it in 5 quarters since.
  • 208 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on Vestal Point Capital's 13F filing for Q2 2026, filed 14 Aug 2026.